Nouvelles AMMs : nivolumab plus ipilimumab dans le cancer colorectal métastatique MSI ou dMMR après échec d’une chimiothérapie
Authors:
- 29 October 2021
- journal article
- editorial
- Published by Elsevier in Bulletin du Cancer
- Vol. 109 (1) , 3-4
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerNew England Journal of Medicine, 2020
- Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal CancerThe Oncologist, 2019
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerJournal of Clinical Oncology, 2018